Tianyu Pharma's 2026 interim net profit was 104 million yuan, down 32.12% year on year

Earnings
โดย Jiemian·CN·Read original
Summary · why it matters

Tianyu Pharma released its 2026 interim report. Total operating revenue was 2.011 billion yuan, and net profit attributable to the parent company was 104 million yuan, down 32.12% from the same period last year. Net cash inflow from operating activities was 416 million yuan, the asset-liability ratio was 47.65%, the gross margin was 30.14%, and diluted earnings per share was 0.30 yuan. The company had 14,100 shareholders, and the top ten shareholders held 66.08% of the shares.

Impact on stocks 1

Others▼ · 1 stocks
© 2026 MarketDXNews